European Urology remains at the top of our field in Nephrology and Urology. With the new IF of 25.3, over 2 million website downloads, and 39.1k followers on Twitter we are constantly striving to be a cut above the rest! Thank you to our Authors, Reviewers, and Readership!

Spotlight: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent by @philcornford et al Full article here: #eauguidelines #ProstateCancer #PCa #eauguidelines2024update #Spotlightarticle #eururol #urosome #MedTwitter

✨ 2024 Reviewers of the Year ✨ Our final Reviewer of the year is Dr. Elio Mazzone. Congratulations @elio_mazzone, and thank you for your time, energy and dedication to The Platinum Journal! #UroSoMe #MedTwitter #ROTY #ReviewOfTheYear

✨ 2024 Reviewers of the Year ✨ Our second Reviewer of the year is Dr. Umang Swami. Congratulations @umangtalking, and thank you for your time, energy and dedication to The Platinum Journal! #UroSoMe #MedTwitter #ROTY #ReviewOfTheYear

✨ 2024 Reviewers of the Year ✨ Our first Reviewer of the year is Prof. Arun Azad. Congratulations @AzadOncology, and thank you for your time, energy and dedication to The Platinum Journal! #UroSoMe #MedTwitter #ROTY #ReviewOfTheYear

Reply to Rongkang Li, Lei Peng, Shaohua Zhang, and Song Wu’s Letter to the Editor re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium by Johan Bjerner et al Read the full Reply here: #UroSoMe #MedTwitter #eururol #LettertotheEditorReply #ProstateCancer #PCa

Letter to the Editor: Re: Johan Bjerner, Ola Bratt, Kirsti Aas, et al. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium by Rongkang Li, Lei Peng et al Read the full Letter here: Come back later for the Author's reply! #UroSoMe #MedTwitter #eururol #LettertotheEditor #ProstateCancer #PCa

SPOTLIGHT: Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial by @nickva1 Read the full article here: #UroSoMe #MedTwitter #eururol #EditorsChoice #spotlight @GGiannarini @PellegrinoMD

Editor's Choice: Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial by @nickva1 et al Read the full article here: Come back to read the Editorial! #UroSoMe #MedTwitter #eururol #EditorsChoice #ProstateCancer #PCa #Spotlight @GGiannarini

Brief Report: Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium by @DrTakemura et al Read the full article here: #UroSoMe #MedTwitter #BriefReport #eururol

Editorial: Refinement of Risk Stratification Is Important for Guiding Treatment and Surveillance Recommendations by @DrWoldu and Yair Lotan Read the full Editorial here: #UroSoMe #MedTwitter #eururol #Editorial

EAU Guidelines - Editor's Choice: European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update by @paolo_gontero et al Read the full article here: Come back later for the Editorial! #UroSoMe #MedTwitter #EAUGuidelines #EAU #eururol #EditorsChoice

Reply to Christopher Guske, Seyed Behzad Jazayeri, and Roger Li’s Letter to the Editor re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? by @AmandaMyersMD Read the full Reply here: #UroSoMe #MedTwitter #eururol

Letter to the Editor: Re: Robert Seifert, Louise Emmett, Steven P. Rowe, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2) by @MUnterrainerMD et al Read the full Letter here: #UroSoMe #MedTwitter #LettertotheEditor #eururol

Words of Wisdom Wednesday: Re: Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening. The STHLM3-MRI Randomized Clinical Trial by Hyerin Park Read the full article here: #UroSoMe #MedTwitter #WoWWednesday #eururol

Words of Wisdom Wednesday: Re: [177Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial by @elio_mazzone Read the full article here: #UroSoMe #MedTwitter #WoWWednesday #eururol

Words of Wisdom Wednesday: Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer by David C. Chen et al Read the full article here: #UroSoMe #MedTwitter #WoWWednesday #eururol #ProstateCancer #PCa

Reply to Jan Hrudka, Petr Waldauf, and Radoslav Matěj’s Letter to the Editor re: Laura Elst, Gino Philips, Kaat Vandermaesen, et al. Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization by @ElstLaura and @MaartenAlbersen Read the full reply here: #UroSoMe #MedTwitter #PenileCancer #eururol #LettertotheEditorReply

Letter to the Editor: Re: Laura Elst, Gino Philips, Kaat Vandermaesen, et al. Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization. by Jan Hrudka et al Read the full article here: Come back later to see the Author's reply! #UroSoMe #MedTwitter #PenileCancer #eururol #LettertotheEditor

Editorial: Correlating Prostate-specific Antigen Dynamics with Outcomes of Lutetium-177-PSMA-617 Treatment: Refining Predictive and Prognostic Biomarkers by @chadihc98 et al Read the full Editorial here: #UroSoMe #MedTwitter #eururol #Editorial

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial by @AarmstrongDuke et al Read the full article here: And check back later for the Editorial by @chadihc98 et al #UroSoMe #MedTwitter #PCa #ProstateCancer #eururol @GGiannarini